MedTrace Logo

Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis

NCT00449345 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2007-05-30

No results posted yet for this study

Summary

The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.

In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays.

In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers.

We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.

Conditions

  • Latent Tuberculosis Infection

Interventions

PROCEDURE

Blood test for Quantiferon-GOLD assay

Sponsors & Collaborators

  • Maccabi Healthcare Services, Israel

    collaborator OTHER

  • Assuta Hospital Systems

    lead OTHER

Principal Investigators

  • David Shitrit, MD · Maccabi Healthcare Services, Israel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449345 on ClinicalTrials.gov